Oragenics (OGEN) Stock Price, News & Analysis

Company Overview

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Key Stats

• Today's Range: $4.13 to $4.83
• 50-Day Range: $3.53 to $6.06
• 52-Week Range: $3.12 to $75.60
• Volume: 80,798 shs
• Average Volume: 105,245 shs
• Market Capitalization: $3.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Oragenics Stock Analysis - MarketRank™

Oragenics scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oragenics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oragenics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oragenics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oragenics has a P/B Ratio of 7.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.98% of the float of Oragenics has been sold short.

Short Interest Ratio / Days to Cover

Oragenics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oragenics has recently decreased by 90.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oragenics does not currently pay a dividend.

Dividend Growth

Oragenics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.98% of the float of Oragenics has been sold short.

Short Interest Ratio / Days to Cover

Oragenics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oragenics has recently decreased by 90.95%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.33

News Sentiment

Oragenics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Oragenics this week, compared to 1 article on an average week.

Search Interest

1 people have searched for OGEN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oragenics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.90% of the stock of Oragenics is held by insiders.

Percentage Held by Institutions

Only 18.71% of the stock of Oragenics is held by institutions.

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed this year?

Oragenics' stock was trading at $11.0790 at the start of the year. Since then, OGEN stock has decreased by 60.6% and is now trading at $4.36.
View the best growth stocks for 2025 here.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSE:OGEN) released its quarterly earnings data on Monday, August, 16th. The company reported ($54.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($72.00) by $18.00.

When did Oragenics' stock split?

Shares of Oragenics reverse split before market open on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), iBio (IBIO), Jaguar Health (JAGX), NIO (NIO), Bionano Genomics (BNGO) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 8/16/2021
• Today: 6/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:OGEN
• Previous Symbol: NYSE:OGEN
• CIK: 1174940
• Web: www.oragenics.com
• Phone: 813-286-7900
• Fax: 813-286-7904
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($33.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.66 million
• Net Margins: N/A
• Pretax Margin: -243,950.00%
• Return on Equity: -2,087.95%
• Return on Assets: -486.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.93
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 77.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 7.15

Miscellaneous

• Outstanding Shares: 715,000
• Free Float: 10,979,000
• Market Cap: $3.12 million
• Optionable: N/A
• Beta: 0.94